Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2013, Article ID 614242, 6 pages
http://dx.doi.org/10.1155/2013/614242
Research Article

Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients

1The Department of Internal Medicine, The Affiliated Hospital of Medical College, Qingdao University, Qingdao 266100, China
2Department of Endocrinology, Key Laboratory of Endocrinology, Fujian Provincial Hospital, Fujian Medical University, North Branch of Fujian Provincial Hospital, Fujian Provincial Geriatric Hospital, Fuzhou 350001, China

Received 16 May 2012; Revised 27 March 2013; Accepted 13 April 2013

Academic Editor: Anil K. Agarwal

Copyright © 2013 Wen-shan Lv et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. L. Wajchenberg, “β-cell failure in diabetes and preservation by clinical treatment,” Endocrine Reviews, vol. 28, no. 2, pp. 187–218, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Weng, Y. Li, W. Xu et al., “Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial,” The Lancet, vol. 371, no. 9626, pp. 1753–1760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Retnakaran, N. Yakubovich, Y. Qi, C. Opsteen, and B. Zinman, “The response to short-term intensive insulin therapy in type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 12, no. 1, pp. 65–71, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Fujita, M. Fukushima, H. Suzuki et al., “Short-term intensive glycemic control improves vibratory sensation in type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 80, no. 1, pp. e16–e19, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Ruxer, M. Mozdzan, L. Czupryniak, M. Saryusz-Wolska, and J. Loba, “Effectiveness of selected methods of the short-term intensive insulin therapy in patients with poorly controlled type 2 diabetes mellitus,” Polskie Archiwum Medycyny Wewnetrznej, vol. 112, no. 2, pp. 945–952, 2004. View at Google Scholar · View at Scopus
  6. M. Guvener, I. Pasaoglu, M. Demircin, and M. Oc, “Perioperative hyperglycemia is a strong correlate of postoperative infection in type II diabetic patients after coronary artery bypass grafting,” Endocrine Journal, vol. 49, no. 5, pp. 531–537, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Timsit and D. Dubois-Laforgue, “Should the occurrence of a first coronary event change the management of diabetes?” Archives des Maladies du Coeur et des Vaisseaux, vol. 93, no. 4, pp. 39–44, 2000. View at Google Scholar · View at Scopus
  8. A. Liebl, “Challenges in optimal metabolic control of diabetes,” Diabetes/Metabolism Research and Reviews, vol. 18, supplement 3, pp. S36–S41, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. J. C. Pickup and E. Renard, “Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes,” Diabetes Care, vol. 31, supplement 2, pp. S140–145, 2008. View at Google Scholar · View at Scopus
  10. V. Lassmann-Vague, S. Clavel, B. Guerci et al., “When to treat a diabetic patient using an external insulin pump. Expert consensus. Société francophone du diabète (ex ALFEDIAM) 2009,” Diabetes and Metabolism, vol. 36, no. 1, pp. 79–85, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. P. E. Cryer, “Defining and reporting hypoglycemia in diabetes: a report from the American diabetes association workgroup on hypoglycemia,” Diabetes Care, vol. 28, no. 5, pp. 1245–1249, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Sheldon, D. Russell-Jones, and J. Wright, “Insulin analogues: an example of applied medical science,” Diabetes, Obesity and Metabolism, vol. 11, no. 1, pp. 5–19, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. D. R. Owens and G. B. Bolli, “Beyond the era of NPH insulin—long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application,” Diabetes Technology and Therapeutics, vol. 10, no. 5, pp. 333–349, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Heise and T. R. Pieber, “Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies,” Diabetes, Obesity and Metabolism, vol. 9, no. 5, pp. 648–659, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. J. H. DeVries, M. Nattrass, and T. R. Pieber, “Refining basal insulin therapy: what have we learned in the age of analogues?” Diabetes/Metabolism Research and Reviews, vol. 23, no. 6, pp. 441–454, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. S. G. Swinnen, A. C. Simon, F. Holleman, J. B. Hoekstra, and J. H. Devries, “Insulin detemir versus insulin glargine for type 2 diabetes mellitus,” Cochrane Database of Systematic Reviews, no. 7, Article ID CD006383, 2011. View at Google Scholar · View at Scopus
  17. J. Rosenstock, M. Davies, P. D. Home, J. Larsen, C. Koenen, and G. Schernthaner, “A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes,” Diabetologia, vol. 51, no. 3, pp. 408–416, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. B. King, “Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study,” Diabetes, Obesity and Metabolism, vol. 11, no. 1, pp. 69–71, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Hollander, J. Cooper, J. Bregnhøj, and C. B. Pedersen, “A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes,” Clinical Therapeutics, vol. 30, no. 11, pp. 1976–1987, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Raslova, “An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog,” Vascular Health and Risk Management, vol. 6, pp. 399–410, 2010. View at Google Scholar · View at Scopus
  21. M. L. Marcovecchio, M. Lucantoni, and F. Chiarelli, “Role of chronic and acute hyperglycemia in the development of diabetes complications,” Diabetes Technology and Therapeutics, vol. 13, no. 3, pp. 389–394, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. C. R. Marling, J. H. Shubrook, S. J. Vernier, M. T. Wiley, and F. L. Schwartz, “Characterizing blood glucose variability using new metrics with continuous glucose monitoring data,” Journal of Diabetes Science and Technology, vol. 5, no. 4, pp. 871–878, 2011. View at Google Scholar
  23. A. Ceriello and M. A. Ihnat, “‘Glycaemic variability’: a new therapeutic challenge in diabetes and the critical care setting,” Diabetic Medicine, vol. 27, no. 8, pp. 862–867, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Bragd, A. von Döbeln, P. E. Lins, U. Adamson, J. Bergström, and P. Oskarsson, “Basal insulin substitution with glargine or continuous subcutaneous insulin infusion in adult type 1 diabetes patients—a randomized controlled trial,” Diabetes Technology and Therapeutics, vol. 12, no. 9, pp. 689–693, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. O. Klein, J. Lynge, L. Endahl, B. Damholt, L. Nosek, and T. Heise, “Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 9, no. 3, pp. 290–299, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Heise, L. Nosek, B. B. Roønn et al., “Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes,” Diabetes, vol. 53, no. 6, pp. 1614–1620, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. M. C. Jones and M. Patel, “Insulin detemir: a long-acting insulin product,” The American Journal of Health-System Pharmacy, vol. 63, no. 24, pp. 2466–2472, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Valensi and E. Cosson, “Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?” Diabetes and Metabolism, vol. 31, no. 4, pp. 4S34–4S39, 2005. View at Google Scholar · View at Scopus
  29. A. Tone, I. Iseda, C. Higuchi et al., “Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes,” Experimental and Clinical Endocrinology and Diabetes, vol. 118, no. 5, pp. 320–324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. G. B. Bolli, “Insulin treatment in type 1 diabetes,” Endocrine Practice, vol. 12, supplement 1, pp. 105–109, 2006. View at Google Scholar · View at Scopus